Progesterone


West-ward Pharmaceuticals Corp
Human Prescription Drug
NDC 0143-9725
Progesterone is a human prescription drug labeled by 'West-ward Pharmaceuticals Corp'. National Drug Code (NDC) number for Progesterone is 0143-9725. This drug is available in dosage form of Injection. The names of the active, medicinal ingredients in Progesterone drug includes Progesterone - 50 mg/1 . The currest status of Progesterone drug is Active.

Drug Information:

Drug NDC: 0143-9725
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Progesterone
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Progesterone
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: West-ward Pharmaceuticals Corp
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:PROGESTERONE - 50 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAMUSCULAR
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 28 Oct, 2010
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 28 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA091033
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:West-Ward Pharmaceuticals Corp
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:312644
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:M0017672
N0000175601
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:4G7DS2Q64Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Progesterone [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Progesterone [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Progesterone [CS]
Progesterone [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0143-9725-0110 INJECTION in 1 BOX (0143-9725-01)28 Oct, 2010N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Progesterone progesterone progesterone progesterone benzyl alcohol sesame oil

Indications and Usage:

Indications and usage this drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.

Warnings:

Warnings the physician should be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, cerebrovascular disorders, pulmonary embolism, and retinal thrombosis). should any of these occur or be suspected, the drug should be discontinued immediately. medication should be discontinued pending examination if there is a sudden partial or complete loss of vision, or if there is a sudden onset of proptosis, diplopia or migraine. if examination reveals papilledema or retinal vascular lesions, medication should be withdrawn. acute eosinophilic pneumonia has been reported in patients receiving progesterone in sesame oil. in reported cases associated with progesterone in sesame oil, patients developed fever, dyspnea with hypoxic respiratory insufficiency, and diffuse pulmonary infiltrates. in general, patients developed eosinophilic pneumonia 2 to 4 weeks after starting progesterone in sesame oil and improved when progesterone in sesame oil was discontinued and a different
formulation of progesterone and/or steroid therapy was initiated. patients who develop these signs and symptoms while receiving progesterone in sesame oil should undergo prompt medical evaluation, and progesterone in sesame oil should be discontinued immediately.

General Precautions:

General the pretreatment physical examination should include special reference to breast and pelvic organs, as well as a papanicolaou smear. because progestational drugs may cause some degree of fluid retention, conditions which might be influenced by this condition, such as epilepsy, migraine, asthma, cardiac, or renal dysfunction, require careful observation. in cases of breakthrough bleeding, as in all cases of irregular bleeding per vaginum, nonfunctional causes should be borne in mind, and adequate diagnostic measures undertaken. patients who have a history of psychic depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree. the age of the patient constitutes no absolute limiting factor although treatment with progestin may mask the onset of the climacteric. the pathologist should be advised of progestin therapy when relevant specimens are submitted. there are possible risks which may be associated with the use of progestin tre
atment, including adverse effects on carbohydrate and lipid metabolism. the dosage used may be important in minimizing these adverse effects. a decrease in glucose tolerance has been observed in a small percentage of patients on estrogen-progestin combination treatment. the mechanism of this decrease is obscure. for this reason, diabetic patients should be carefully observed while receiving such therapy.

Dosage and Administration:

Dosage and administration progesterone injection, usp is administered by intramuscular injection. it differs from other commonly used steroids in that it is irritating at the place of injection. amenorrhea: five to 10 mg are given for six to eight consecutive days. if there has been sufficient ovarian activity to produce a proliferative endometrium, one can expect withdrawal bleeding forty-eight to seventy-two hours after the last injection. this may be followed by spontaneous normal cycles. functional uterine bleeding: five to 10 mg are given daily for six doses. bleeding may be expected to cease within six days. when estrogen is given as well, the administration of progesterone is begun after two weeks of estrogen therapy. if menstrual flow begins during the course of injections of progesterone, they are discontinued. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit.

Contraindications:

Contraindications current or past history of thrombophlebitis, thromboembolic disorders, or cerebral apoplexy. liver dysfunction or disease. known or suspected malignancy of breast or genital organs. undiagnosed vaginal bleeding. missed abortion. known sensitivity to progesterone injection. known sensitivity to sesame oil/seeds.

Adverse Reactions:

Adverse reactions breakthrough bleeding; spotting; change in menstrual flow; amenorrhea; edema; change in weight (increase or decrease); changes in cervical erosion and cervical secretions; cholestatic jaundice; breast tenderness and galactorrhea; pain, irritation, and/or redness at the injection area; skin sensitivity reactions consisting of urticaria, pruritus, edema and generalized rash; acne, alopecia and hirsutism; rash (allergic) with and without pruritus; anaphylactoid reactions (including eosinophilic pneumonia); mental depression; pyrexia; insomnia; nausea; and somnolence. a statistically significant association has been demonstrated between use of estrogen-progestin combination drugs and pulmonary embolism and cerebral thrombosis and embolism. for this reason patients on progestin therapy should be carefully observed. there is also evidence suggestive of an association with neuro-ocular lesions, e.g., retinal thrombosis and optic neuritis. the following adverse reactions have
been observed in patients receiving estrogen-progestin combination drugs: rise in blood pressure in susceptible individual, premenstrual syndrome, changes in libido, changes in appetite, cystitis-like syndrome, headache, nervousness, fatigue, backache, hirsutism, loss of scalp hair, erythema multiforme, erythema nodosum, hemorrhagic eruption, itching, and dizziness. the following laboratory results may be altered by the use of estrogen-progestin combination drugs: increased sulfobromophthalein retention and other hepatic function tests; coagulation tests: increase in prothrombin factors vii, viii, ix, and x; metyrapone test; pregnanediol determinations; thyroid function: increase in pbi, and butanol extractable protein bound iodine and decrease in t 3 uptake values. to report suspected adverse reactions, contact west-ward pharmaceuticals corp at 1-877-233-2001 or fda at 1-800-fda-1088 or www.fda.gov/medwatch .

Description:

Description progesterone injection, usp, a progestin, is a sterile solution of progesterone in a suitable vegetable oil available for intramuscular use. progesterone occurs as a white or creamy white, crystalline powder. it is odorless and is stable in air. practically insoluble in water, it is soluble in alcohol, acetone, and dioxane and sparingly soluble in vegetable oils. it has the following structural formula: c 21 h 30 o 2 m.w. 314.47 pregn-4-ene-3, 20-dione each ml contains: progesterone 50 mg, benzyl alcohol 10% as preservative in sesame oil q.s. progesterone structural formula.

Clinical Pharmacology:

Clinical pharmacology transforms proliferative endometrium into secretory endometrium. inhibits (at the usual dose range) the secretion of pituitary gonadotropins, which in turn prevents follicular maturation and ovulation. pharmacokinetics and metabolism absorption: after intramuscular administration of 10 mg of progesterone in oil, maximum plasma concentrations (geometric mean of 7 ng/ml) were reached within approximately 8 hours after injection and plasma concentrations remained above baseline for about 24 hours after injection. injection of 10, 25, and 50 mg resulted in geometric mean values for maximum plasma concentration (c max ) of 7, 28, and 50 ng/ml, respectively. distribution: progesterone is extensively bound to plasma proteins, primarily albumin (50-54%) and cortisol-binding protein (43-48%). metabolism: progesterone is metabolized primarily in the liver by reduction to pregnanediol, pregnanetriol, and pregnanolone. subsequent conjugation results in the formation of glucur
onide and sulfate metabolites. the mean plasma metabolic clearance rate in cycling women is 2510 ± 135 (sem) l/day. excretion: the glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the urine and bile. progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces. the pharmacokinetic data was determined in a small number of patients, limiting the precision in which population values may be estimated. special populations renal insufficiency: the safety and effectiveness in patients with renal insufficiency have not been established. since progesterone metabolites are excreted mainly by the kidneys, progesterone should be administered with caution and careful monitoring in this patient population (see precautions ). hepatic insufficiency: the safety and effectiveness in patients with hepatic insufficiency have not been established. since progesterone is metabolized by the liver, use in patients with liver dysfunction or disease is contraindicated (see contraindications ). drug interactions the metabolism of progesterone by human liver microsomes was inhibited by ketoconazole (ic 50 < 01 mcm). ketoconazole is a known inhibitor of cytochrome p450 3a4 and these data suggest that ketoconazole or other known inhibitors of this enzyme may increase the bioavailability of progesterone. the clinical relevance of the in vitro findings is unknown.

How Supplied:

How supplied progesterone injection, usp, 50 mg/ml is available in 10 ml multiple dose vials, individually boxed. (ndc 0143-9725-01) store at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. manufactured by: hikma farmacÊutica (portugal), s.a. estrada do rio da mó, 8, 8a e 8b – fervença – 2705-906 terrugem snt, portugal distributed by: west-ward a hikma company eatontown, nj 07724 usa revised: august 2018 pin258-wes/4

Spl Patient Package Insert:

Patient information progesterone injection, usp in sesame oil – for intramuscular use only rx only for the treatment of amenorrhea (absence of menses in women who have previously had a menstrual period) or abnormal uterine bleeding due to hormonal imbalance. please read this information carefully before you start to use progesterone injection and each time your prescription is renewed, in case anything has changed. this leaflet does not take the place of discussions with your doctor. if you still have any questions, ask your doctor or healthcare provider. about progesterone injection progesterone injection is a sterile injectable solution containing the natural female hormone called progesterone. progesterone injection is indicated for the treatment of amenorrhea and abnormal uterine bleeding due to progesterone deficiency. understanding the role of progesterone injection in the treatment of your menstrual irregularities. progesterone is one of the hormones essential for regular m
enstrual periods. if your doctor has determined your body does not produce enough progesterone on its own, progesterone injection may be prescribed to provide the progesterone you need. when you do not produce enough progesterone, menstrual irregularities can occur. progesterone injection can provide you with the progesterone needed during a normal menstrual cycle. possible side effects of progesterone injection the following side effects have been reported with progesterone injection. consult your doctor if you experience any of the side effects mentioned below, or other side effects. anaphylactoid (life-threatening allergic) reaction with symptoms that may include a sense of uneasiness or apprehension; flushing; fast, throbbing heartbeat; itching; hives; difficult breathing; swelling of the throat; eosinophilic pneumonia (gathering of eosinophils, a type of white blood cell, in the lungs), fainting; nausea; vomiting; or convulsions. breakthrough bleeding spotting changes in menstrual flow amenorrhea change in weight (increase or decrease) pain, irritation, swelling, and/or redness at the injection area general swelling vaginal discharge yellow discoloration of skin or white of eyes breast tenderness, discharge from the nipple skin reactions including rash, hives, itching, and swelling acne hair loss or growth of new hair mental depression fever insomnia or sleepiness* nausea *if you experience sleepiness, do not drive or operate machinery. when you should not use progesterone injection if you are allergic to progesterone, progesterone-like drugs, benzyl alcohol or sesame oil/seeds. if you have unusual vaginal bleeding which has not been evaluated by your doctor. if you have liver disease. if you have known or suspected cancer of the breast or genital organs. if you have a miscarriage and your physician suspects some tissue is still in the uterus. if you have or have had blood clots in the legs, lungs, eyes, or elsewhere. risks of progesterone injection abnormal blood clotting. blood clots have been reported with the use of estrogens and progestational drugs (alone or in combination). if blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. these problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), or other problems. any of these conditions may cause death or serious long-term disability. call your doctor immediately if you suspect you have any of these conditions. he or she may advise you to stop using this drug. precautions be alert for unusual signs and symptoms. if any of these warning signals (or any other unusual symptoms) happen while you are using progesterone injection, call your doctor immediately: abnormal bleeding from the vagina. pains in the calves or chest, a sudden shortness of breath or coughing blood indicating possible clots in the legs, heart, or lungs. severe headache or vomiting, dizziness, faintness, or changes in vision or speech, weakness or numbness of an arm or leg indicating possible clots in the brain or eye. breast lumps, which could be associated with fibrocystic disorders, fibroadenoma, or breast cancer. (ask your doctor or healthcare provider to show you how to examine your breasts monthly.) yellowing of the skin and/or white of the eyes indicating possible liver problems. how progesterone injection works progesterone injection is intended for administration by injection into a muscle mass. following injection, the medication is absorbed into the bloodstream. other information your doctor has prescribed this drug for you and you alone. do not give this drug to anyone else. this medication was prescribed for your particular medical condition. do not use it for another condition. keep this and all drugs out of the reach of children. how to use progesterone injection progesterone injection will be administered to you by a healthcare provider or your caregiver. your doctor will provide instructions regarding the dose and manner in which the medication should be injected. follow your doctor’s instructions closely. if you have any questions about product administration, ask your doctor or healthcare provider. how supplied progesterone injection, usp 50 mg/ml is available in 10 ml multiple dose vials. vials are individually boxed. progesterone injection should be stored at 20° to 25°c (68° to 77°f) [see usp controlled room temperature]. do not use progesterone injection after the expiration date which is printed on the vial label. call your doctor for medical advice about side effects. you may report side effects to the fda at 1-800-fda-1088 or www.fda.gov/medwatch. manufactured by: hikma farmacÊutica (portugal), s.a. estrada do rio da mó, 8, 8a e 8b – fervença – 2705-906 terrugem snt, portugal distributed by: west-ward a hikma company eatontown, nj 07724 usa revised: august 2018 pin258-wes/4

Package Label Principal Display Panel:

Principal display panel ndc 0143-9725-01 progesterone injection, usp 500 mg/10 ml (50 mg/ml) sterile for im use only rx only ndc 0143-9725-01 10 ml multiple dose vial progesterone injection, usp 500 mg/10 ml (50 mg/ml) sterile for im use only rx only progesterone injection, usp 500 mg/10 ml pbx408-wes/2

Serialization image layout 1


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.